Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carbetocin Acetate
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Levo Therapeutics Announces Top-line Results from Phase 3 CARE-PWS Study of LV-101
Details : While the study did not meet its primary outcome measurements evaluating the 9.6 mg dose of LV-101 statistical significance was achieved with the 3.2 mg dose as evaluated by the Hyperphagia Questionnaire for Clinical Trials score (p=0.016) as the first s...
Brand Name : LV-101
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 06, 2020
Lead Product(s) : Carbetocin Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?